Corporate Events

From May 14, 2025 to June 30, 2025, the company has repurchased 249,000 shares, representing 0.4% for ¥960.79 million. With this, the company has completed the repurchase of 249,000 shares, representing 0.4% for ¥960.79 million under the buyback announced on May 14, 2025.

Kaneka Corporation Presents at Downstream USA, Jun-25-2025 through Jun-26-2025. Venue: George R. Brown Convention Center, Houston, Texas, United States. Presentation Date & Speakers: Jun-26-2025, Ziyan Sheriff, Senior Process Data Scientist | Digital Transformation & Innovation, Ziyan Sheriff, Senior Process Data Scientist, Digital Transformation & Innovation.

Reuters Events, Downstream USA, Jun 25, 2025 through Jun 26, 2025. Venue: George R. Brown Convention Center, Houston, Texas, United States.

Kaneka Corporation announced year-end dividend of JPY 70.00 per share for the fiscal year ended March 31, 2025 compared to JPY 55.00 per share a year ago. Scheduled date of dividend distribution: June 6, 2025. The company provided second quarter 2026 dividend guidance of JPY 80.00 per share compared to JPY 60.00 per share a year ago. The company provided year-end dividend guidance of JPY 80.00 per share for the fiscal year ending March 31, 2026 compared to JPY 70.00 per share a year ago.

Kaneka Corporation provided consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company expects net sales of JPY 820,000 million, operating income of JPY 42,000 million, net income attributable to owners of parent of JPY 33,000 million and net income per share of JPY 524.36.

The Board of Directors of Kaneka Corporation has authorized a buyback plan on May 14, 2025.

Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury.

Kaneka Corporation, Annual General Meeting, Jun 27, 2025.

Kaneka Corporation, Board Meeting, May 14, 2025. Agenda: To consider and approve the repurchase of treasury stock pursuant to the provisions of Article 459; and to consider and approve the cancellation treasury stock pursuant to Article 178 of the Companies Act.

Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025

Kaneka Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2025. For the year, the company revised net sales of JPY 800,000 million compared to previous guidance of JPY 790,000 million, operating income of JPY 40,000 million compared to previous guidance of JPY 38,000 million, net income attributable to owners of parent of JPY 25,000 million or JPY 396.02 net income per share compared to previous guidance of JPY 24,500 million or JPY 388.18 net income per share.

Kaneka Corporation Presents at Applied Biocatalysis & Enzyme Engineering Summit, Dec-11-2024 10:00 AM. Venue: Philadelphia, Pennsylvania, United States. Speakers: Toru Watanabe, Researcher.

Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030. Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024.

Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025

Kaneka Corporation, ¥ 60.0, Cash Dividend, Mar-28-2025

Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024

Kaneka Corporation opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido for the purpose of portfolio transformation and business expansion and held the opening ceremony on August 26. The Tomatoh Manufacturing Site is the seventh domestic business location*1 for the company and the first new one in 54 years. The medical device plant*2 completed at Tomatoh Manufacturing Site will produce adsorption type blood purification devices "Rheocarna™" and adsorption type plasma purification devices "Liposorber™". The number of patients with arteriosclerosis obliterans (ASO)*3, which these medical devices are intended to treat, is on the rise worldwide, along with increases in diabetes, chronic renal failure, and other conditions. By securing the supply base through the new plant, it will dramatically expand its medical business to meet global demand. The plant has achieved full automation of its production lines as a "smart factory" utilizing robot technology and plans to realize a "zero energy factory" that will reduce the primary energy consumption of the factory building to zero by using it photovoltaic modules, thereby promoting sustainable manufacturing. In the future, Tomatoh Manufacturing Site will be actively utilized as a new production base for each business, as well as for further expansion of the medical business.